Glioblastoma, IDH-wildtype Clinical Trials in Rochester, Minnesota

4 studies are recruiting for glioblastoma, idh-wildtype in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

    This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkylating agents. It wo…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Locations
    3 in total
    Run by
    Mayo Clinic

    See if you can join NCT07708961 on ClinicalTrials.gov

  2. Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

    This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximat…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Locations
    3 in total
    Run by
    Mayo Clinic

    See if you can join NCT07091864 on ClinicalTrials.gov

  3. Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

    This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlima…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Run by
    Mayo Clinic

    See if you can join NCT07468136 on ClinicalTrials.gov

  4. GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

    This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or g…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Run by
    Mayo Clinic

    See if you can join NCT07301268 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.